Preferred Label : Lipodystrophy, partial, acquired, susceptibility to;
Symbol : APLD;
CISMeF acronym : APLD;
Type : Phenotype, molecular basis known;
Alternative titles and symbols : Apld, susceptibility to; Lipodystrophy, partial, progressive; Lipodystrophy, cephalothoracic type; Barraquer-simons syndrome;
Description : Acquired partial lipodystrophy is characterized clinically by the gradual onset of
bilaterally symmetrical loss of subcutaneous fat from the face, neck, upper extremities,
thorax, and abdomen, in the 'cephalocaudal' sequence, sparing the lower extremities
(summary by Misra et al., 2004). The disorder is not inherited in a classic mendelian
pattern; it rather represents a phenotype with a complex etiology. Affected individuals
may have genetic susceptibility factors that require the additional presence of environmental
factors or acquired disorders to be expressed (summary by Hegele et al., 2006). Most
cases are sporadic, family history is negative, and females are more often affected
than males (ratio, 4:1). There is an association between APLD and autoimmune diseases
(Misra and Garg, 2003; Misra et al., 2004), and a subset of patients have APLD associated
with low serum complement component C3 and the autoantibody C3 nephritic factor, with
or without membranoproliferative glomerulonephritis (APLDC3; 613913). Acquired partial
lipodystrophy is distinct from inherited forms of partial lipodystrophy, which are
metabolic disorders that show clear mendelian inheritance (see, e.g., FPLD1, 608600).;
Inheritance : Autosomal dominant;
Molecular basis : Susceptibility conferred by mutation in the lamin B2 gene (LMNB2, 150341.0001);
Laboratory abnormalities : Dyslipidemia;
Prefixed ID : #608709;
Origin ID : 608709;
UMLS CUI : C3887501;
Automatic exact mappings (from CISMeF team)
Currated CISMeF NLP mapping
False automatic mappings
Genes related to phenotype
HPO term(s)
ORDO concept(s)
Semantic type(s)